At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 808 enrolled
Drug / intervention
losartan potassium (+) hydrochlorothiazide +1 moredrug
Likely dose
losartan potassium (+) hydrochlorothiazide 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BP-EASE-A 12-Week, Multicenter, Open-Label, Randomized, Controlled Trial To Compare The Effectiveness of Losartan 50 mg/HCTZ 12.5 mg Titrated as Needed to Losartan 100 mg/HCTZ 25 mg or Valsartan 160 mg/HCTZ 25 mg, in Patients With Essential Hypertension Who Have Not Achieved Target Blood Pressure With
In Brief
A Phase 3 clinical trial evaluating losartan potassium (+) hydrochlorothiazide and Comparator: Valsartan (+) Hydrochlorothiazide for Hypertension. Completed, enrolled 808 participants.
Detailed Summary
To evaluate the blood pressure efficacy between losartan and valsartan at equivalent dosage during a 3 months treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedOct 2007
Primary CompletionApr 2009
Study CompletionMay 2009
TodayJul 2026
First PostedOct 19, 2007
Enrollment StartMay 1, 2007
Primary CompletionApr 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.7 years ago
Interventions
losartan potassium (+) hydrochlorothiazidedrug
losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
Comparator: Valsartan (+) Hydrochlorothiazidedrug
Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide